ArticlePloS one2016
Decreased TUSC3 Promotes Pancreatic Cancer Proliferation, Invasion and Metastasis.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 24 citations in OpenAlex.
- Involvement of tumor suppressor candidate 3 in mouse survival, craniofacial, and cortical development.G3 (Bethesda, Md.) · 2026Article
- Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status.International journal of molecular sciences · 2023Article
- aCGH Analysis Reveals Novel Mutations Associated with Congenital Diaphragmatic Hernia Plus (CDH+).Journal of clinical medicine · 2023Article
- Downregulation of TUSC3 promotes EMT and hepatocellular carcinoma progression through LIPC/AKT axis.Journal of translational medicine · 2022Article
- TUSC3 inhibits cell proliferation and invasion in cervical squamous cell carcinoma via suppression of the AKT signalling pathway.Journal of cellular and molecular medicine · 2022Article
- Downregulation of microRNA-320a inhibits proliferation and induces apoptosis of retinoblastoma cells via targeting TUSC3.Experimental and therapeutic medicine · 2020Article
- Article
- A 21‑gene Support Vector Machine classifier and a 10‑gene risk score system constructed for patients with gastric cancer.Molecular medicine reports · 2020Article
- TUSC3 as a potential biomarker for prognosis in clear cell renal cell carcinoma.Oncology letters · 2019Article
- regQTLs: Single nucleotide polymorphisms that modulate microRNA regulation of gene expression in tumors.PLoS genetics · 2018Article
- TUSC3: functional duality of a cancer gene.Cellular and molecular life sciences : CMLS · 2018Review
- Subgroup analysis reveals molecular heterogeneity and provides potential precise treatment for pancreatic cancers.OncoTargets and therapy · 2018Article
- MicroRNA-132 induces temozolomide resistance and promotes the formation of cancer stem cell phenotypes by targeting tumor suppressor candidate 3 in glioblastoma.International journal of molecular medicine · 2017Article
- TUSC3 induces autophagy in human non-small cell lung cancer cells through Wnt/β-catenin signaling.Oncotarget · 2017Article
- HCMV-encoded miR-UL112-3p promotes glioblastoma progression via tumour suppressor candidate 3.Scientific reports · 2017Article
- Effects of RNAi-mediated TUSC3 silencing on radiation-induced autophagy and radiation sensitivity of human lung adenocarcinoma cell line A549 under hypoxic condition.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- TUSC3 suppresses glioblastoma development by inhibiting Akt signaling.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Diagnostic value of selected markers and apoptotic pathways for pancreatic cancer.Central-European journal of immunology · 2016Review
- Correction: Decreased TUSC3 Promotes Pancreatic Cancer Proliferation, Invasion and Metastasis.PloS one · 2016Article
Corrections and comments
- Erratum issued
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer is an aggressive disease with dismal prognosis. It is of paramount importance to understand the underlying etiological mechanisms and identify novel, consistent, and easy-to-apply prognostic factors for precision therapy. TUSC3 (tumor suppressor candidate 3) was identified as a potential tumor suppressor gene and previous study showed TUSC3 is decreased in pancreatic cancer at mRNA level, but its putative tumor suppressor function remains to be verified. In this study, TUSC3 expression was found to be suppressed both at mRNA and protein levels in cell line models as well as in clinical samples; decreased TUSC3 expression was associated with higher pathological TNM staging and poorer outcome. In three pairs of cell lines with different NF-κB activity, TUSC3 expression was found to be reversely correlated with NF-κB activity. TUSC3-silenced pancreatic cancer cell line exhibited enhanced potential of proliferation, migration and invasion. In an orthotopic implanted mice model, TUSC3 silenced cells exhibited more aggressive phenotype with more liver metastasis. In conclusion, the current study shows that decreased immunological TUSC3 staining is a factor prognostic of poor survival in pancreatic cancer patients and decreased TUSC3 promotes pancreatic cancer cell proliferation, invasion and metastasis. The reverse correlation between NF-κB activity and TUSC3 expression may suggest a novel regulation pattern for this molecule.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.